BG-505NP
- Generic Name
- BG-505NP
A Clinical Trial to Evaluate the Safety and Immunogenicity of Glycan-trimmed HIV-1 Nanoparticle Vaccine (UVAX-1107), Followed by Homologous or Wild-type HIV-1 Nanoparticle Vaccine (UVAX-1197) Boost, Each Adjuvanted With 3M-052-AF + Alum in Adult Participants Without HIV
Phase 1
Not yet recruiting
- Conditions
- HIV-1-infection
- Interventions
- First Posted Date
- 2025-04-01
- Last Posted Date
- 2025-04-01
- Target Recruit Count
- 25
- Registration Number
- NCT06905275
- Locations
- 🇺🇸
University of Alabama - Birmingham, Birmingham, Alabama, United States
🇺🇸University of Rochester Medical Center, Rochester, New York, United States
🇺🇸Columbia University, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath